Integrating Comorbidity Knowledge for Alzheimer's Disease Drug Repurposing using Multi-task Graph Neural Network

Ko-Hong Lin1, Kang-Lin Hsieh1, Xiaoqian Jiang1

  • 1Center for Secure Artificial Intelligence for Healthcare, School of Biomedical Informatics, University of Texas Health Science Center, Houston, TX, USA.

Insights

This study introduces a novel graph neural network (GNN) pipeline to identify potential Alzheimer's Disease (AD) drug repurposing candidates by analyzing shared causes between AD and vascular diseases. The method successfully predicted drugs with potential therapeutic benefits for AD.

Area of Science:

  • Biomedical Informatics
  • Computational Neuroscience
  • Pharmacology

Background:

  • Alzheimer's Disease (AD) is complex, sharing origins with comorbidities like vascular diseases.
  • Leveraging knowledge from these comorbidities can aid in discovering new AD treatments.
  • Existing therapeutic strategies for AD often fall short, necessitating novel approaches.

Purpose of the Study:

  • To develop a computational pipeline for predicting repurposable drugs for Alzheimer's Disease (AD).
  • To utilize knowledge from AD's common comorbidities, particularly vascular diseases, for drug discovery.
  • To integrate genetic markers, therapeutics, and disease interactions within a graph neural network framework.

Main Methods:

  • A multi-task graph neural network (GNN) pipeline was developed.
  • The pipeline incorporated biomedical interactomes, genetic markers, and therapeutics of AD and related vascular diseases.
  • Drug candidates were predicted using node embedding similarity within the network.

Main Results:

  • The GNN pipeline accurately captured disease interactions and enabled classification.
  • Predicted drug candidates demonstrated high blood-brain barrier (BBB) permeability.
  • Literature review supported the potential of candidate drugs in treating AD pathologies, symptoms, or co-occurring conditions.

Conclusions:

  • The proposed pipeline offers a viable strategy for repurposing drugs for AD.
  • This approach effectively predicts drug candidates by analyzing biological interplays between AD and vascular diseases.
  • The findings highlight the potential of computational methods in accelerating AD drug discovery.